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Fabry disease is a rare X-linked disorder caused by mutations in the
GLA gene encoding the lysosomal enzyme α-galactosidase A. Hemizy-
gous men and heterozygous women can develop cardiac phenotype
[1]. The characteristic cardiac phenotype is left ventricular hypertrophy
mimicking hypertrophic cardiomyopathy or hypertensive heart disease.
Enzyme replacement therapy (ERT) has proven to be effective in
removing glycosphyngolipids from the affected tissues in Fabry disease.
Yet the effects of ERT on Fabry cardiomyopathy critically depend on the
stage of the disease at baseline. ERT provides limited beneﬁt on cardiac
structural changes or exercise capacity in patients with evidence of
ﬁbrosis in cardiac magnetic resonance imaging [2].
In 2002, a 50-year-old woman was diagnosed with cardiac Fabry
disease and commenced a routine of regular outpatient care once
every 1 to 2 months. She has received ERT with regular administration
of recombinant agalsidase (every other week) since 2004, when the
drug became available in Japan. Electrocardiography at the start of ERT
showed sinus arrest, an accelerated junctional rhythm, and high
voltages with T-wave changes. Echocardiography revealed a normal
ejection fraction (74%) with concentric left ventricular hypertrophy
(IVS/PWth, 14/13 mm), especially at the apical site (16 mm), and
dilation of the left atria (diameter 44 mm). Renal function remained
stable with normal plasma creatinine values and no evidence of
proteinuria, a condition highly prevalent in both systemic and cardiac
Fabry diseases. In 2009, however, her cardiac structural changes
progressed as follows in spite of the ongoing ERT: IVS/PWth, 22/
15 mm; apical thickness, 20 mm; and left atrial diameter, 49 mm. Her
proteinuria also slightly progressed to 1+, as determined by qualitative
dipstick testing.
After 7 years on ERT, the patient's exertional dyspnea gradually
worsened with emerging atrial ﬁbrillation and frequent premature
ventricular complexes. Proteinuria deteriorated in qualitative testing
from 1+ to 3+. The symptom remained unresolved even after
carvedilol, angiotensin-converting enzyme inhibitor, diuretics, and
warfarin were introduced. Finally, in 2012, she was referred the
outpatient cardiac rehabilitation clinic at our hospital to participate in
an exercise program. The program was composed of supervised
sessions performed 1 to 2 times a week for 5 months with daily home
exercise. The exercise intensity of the cycle ergometer was determined
at a workload below the anaerobic threshold (AT) obtained in
symptom-limited cardiopulmonary exercise testing (CPET). The
home-based exercise was performed on a cycle ergometer at an intensity
below the AT for 30 min.http://dx.doi.org/10.1016/j.ijcme.2016.09.007
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the patient's exertional dyspnea disappeared and her self-reported
daily activity improved. According to a CPET analysis, the exercise
therapy remarkably increased her levels of oxygen consumption (VO2)
at AT and peak points (Fig. 1A). Ventilatory efﬁciency (VE/VCO2-slope)
after the program was also markedly ameliorated compared to the
baseline (Fig. 1B). Thickness of rectus femoris was evaluated as a
skeletal muscle mass by B-mode ultrasonography, wall tracking ultra-
sound systemwith a 12MHz linear array transducer as described previ-
ously [3]. The transducer was placed at the half point along the length
between the epicondylus lateralis and trochanter major of the femur,
with abundant use of contact gel and minimal pressure to avoid com-
pression of the muscle. The diameter of the rectus femoris after the ex-
ercise program was increased compared with that before the program
(Fig. 2). The level of proteinuria and cardiac structure depicted by echo-
cardiography, however, were unchanged during the program. We
therefore had the patient continue performing home exercise at a high
frequency (3 to 5 times a week) after the program was completed.
Her symptom-free status was maintained and no events requiring
hospitalization occurred. Her urine was tested in every ambulatory
visit. Intriguingly, the degree of proteinuria remarkably improved
from 3+ to trace or negative one year after the completion of the
cardiac rehabilitation program.
In this case, the patient's cardiac involvement and symptoms
worsened even under the ERT. Restrained by her condition, she led a
sedentary lifestyle. Physical inactivity in addition to her cardiac
condition could have led to muscle wasting, further reducing her
exercise capacity and exacerbating her symptoms. Though no reports
have demonstrated exercise therapy to beneﬁt the clinical outcome of
cardiac Fabry disease, either with or without ERT, we encouraged her
to participate in the cardiac rehabilitation program with her informed
consent.
Cardiac rehabilitation exercise training has been shown to improve
clinical status and clinical outcomes in patients with chronic heart
failure [4]. Endurance-type exercise training favorably affects peak
VO2, central hemodynamic function, autonomic function, peripheral
vascular and muscle function, and exercise capacity in chronic heart
failure patients [5]. These adaptations result in an exercise training
effect that allows individuals to exercise to higher peak workloads
or to the same submaximal workload at a lower heart rate and
perceived effort [6]. Daily activities are performed with less dyspnea
and fatigue. The present case also showed improvements in peak
VO2, ventilator efﬁcacy, and symptoms after completion of the
program. Peak VO2 and VE/VCO2-slope are both strong predictive
factors for survival outcome of patients with chronic heart failure
[7]. Histopathological studies revealed a direct skeletal muscle in-
volvement in Fabry disease [8]. In our case, however, the rectus
femoris muscle was thickened in response to the exercise training.
The ongoing exercise training over a longer period also ameliorated
the degree of proteinuria. Exercise-based cardiac rehabilitation hase under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Exercise capacity and ventilatory efﬁciency in CPET analysis before and after exercise-based cardiac rehabilitation (CR) program. (A) V-slope (B) VE/VCO2 slope.
Fig. 2.Ultrasonography for assessing thickness of rectus femorismuscle. (A) B-mode images before (left) and after (right) cardiac rehabilitation. (B)Measurement ofmuscle thickness. The
diameter of the rectus femoris after the exercise program was increased compared with that before the program.
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syndromes [9,10].
ERTprovides indispensable effects in improving clinical outcomes and
extending life expectancy in Fabry disease. The therapy, however, seems
insufﬁcient for patients now that they are living longer. Concomitantly
with ERT, we need to recognize that patients with Fabry disease may be
able to derive equally indispensable beneﬁts from a comprehensive pro-
gram of cardiac rehabilitation incorporating supervised exercise training,
nutritional care, and counseling.
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